Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono to present oncology data at ASCO

Merck Serono to present oncology data at ASCO

24th May 2010

Merck Serono will attend next month’s annual meeting of the American Society of Clinical Oncology (ASCO) to demonstrate its latest cancer care innovations.

New trial data on drugs such as Erbitux and cilengitide will be presented by the company at the ASCO event, as well as analysis on the impact of KRAS testing and personalised therapy in managing metastatic colorectal cancer.

In addition, the company will also highlight the clinical progress of a number of earlier-stage development products, such as the MEK inhibitor AS703026.

Dr Wolfgang Wein, executive vice-president of oncology at Merck Serono, expressed confidence that the company’s focus on biomarker identification in cancer care represents a trend which will bring benefits to patients.

He said: “We believe we have helped spearhead a movement within the oncology community to drive innovations that may change cancer management.”

Last week, the company announced a five-year extension of its international licensing deal for the fertility treatment Crinone, which is produced by Columbia Laboratories.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.